Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...

In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

The first ‘real-world study’ into the weight loss drug, Mounjaro, has now started in Greater Manchester. Thousands of ...

Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

One of the reasons for the internal disagreement at the club was the fact that the nutritionist Eduardo Rauen, who has been ...

Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.